Occurrence and clinical management of moderate-to-severe adverse events during drug-resistant tuberculosis treatment: a retrospective cohort study

Table 4 Relationship between occurrence of moderate-to-severe AEs, medical actions to manage the AEs and their outcome

		Stratified analysis
Medical actions taken to manage AEs and outcome of AEs	Entire cohort analysis	HIV positive stratum	HIV negative stratum
Dose reduced or medicine stopped	3.8 (1.2-11.8)	4.2 (0.6-28.8)	4.1 (1.02-16.2)
Dose reduced or medicine stopped	p = 0.007	p = 0.09	p = 0.04
Adjunctive therapy to treat AE symptoms	1.2 (0.5-2.7)	1.1 (0.4-2.8)	0.8 (0.1-6.0)
Adjunctive therapy to treat AE symptoms	p = 0.74	p = 0.61	p = 0.67
Regimen changed	0.5 (0.2-1.8)	0.5 (0.1-2.6)	0.6 (0.1-4.3)
Regimen changed	p = 0.31	p = 0.37	p = 0.50
Adverse events lasting ≥ 3 months	3.1 (1.4-7.2)	3.6 (1.03-12.5)	1.9 (0.5-7.2)
Adverse events lasting ≥ 3 months	p = 0.002	p = 0.009	p = 0.33

Numbers represent risk ratio (RR) point estimates, their corresponding 95% confidence intervals in brackets, and p-values; HIV = human immunodeficiency virus; AEs = adverse events.

ISSN: 2052-3211